Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%. Elsewhere ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...